Table 1:
Characteristics of BC samples analysed
| Parameters | Eastern SSA n = 444 (35.9%) | Central SSA n = 99 (8.0%) | Southern SSA n = 242 (19.6%) | Western SSA n = 452 (36.5%) | Caucasians n = 117 |
|---|---|---|---|---|---|
|
| |||||
| Countries (N) | Ethiopia (289)* | Congo (99) | Namibia (137)* | Ivory Coast (94) | Germany (117) |
| Malawi (16) | South Africa (105)* | Mali (83) | |||
| Mauritius (72) | Nigeria (275)* | ||||
| Uganda (67)* | |||||
|
| |||||
| Woman of Black Ethnicity (%) | 100% | >95% | >95% | >95% | 0% |
|
| |||||
| Mean age (range) | 46.6 (16–97) | 49.1 (27–86) | 55.5 (25–97) | 47.6 (22–91) | 64.3 (35–85) |
| Tumor size (cm) | |||||
| <5 (% of known) | 173 (64.6%) | 7 (13.2%) | 100 (42.7%) | 72 (37.9%) | 71 (60.7%) |
| >5 (% of known) | 95 (35.4%) | 46 (96.8%) | 134 (57.3%) | 118 (62.1%) | 46 (39.3%) |
| Unknown | 176 | 46 | 8 | 190 | NA |
|
| |||||
| Simplified tumor stage | |||||
| Early | 192 (43.2%) | 7 (7.0%) | 100 (41.2%) | 87 (19.2%) | 71 (60.7%) |
| Advanced | 139 (31.1%) | 46 (46.5%) | 134 (55.4%) | 168 (37.2%) | 46 (39.3%) |
| Unknown | 113 (25.5%) | 46 (46.5%) | 8 (3.3%) | 197 (43.6%) | 0 (0.0%) |
|
| |||||
| Available survival data | 139 (31.3%) | 0 (0,0%) | 192 (79.3%) | 69 (16.2%) | 0 (0.0%) |
|
| |||||
| Number of patients alive after 3 years follow-up | 80 (57.5%) | NA | 129 (67.2%) | 26 (35.6%) | NA |
|
| |||||
| Histology | |||||
| NST | 365 (82.2%) | 89 (89.8%) | 194 (80.2%) | 390 (86.2%) | 87 (74.4%) |
| non NST | 79 (17.8%) | 10 (10.2%) | 48 (19.8%) | 62 (13.8%) | 30 (25.6%) |
|
| |||||
| Grading | |||||
| G1 | 23 (5.2%) | 3 (3.0%) | 40 (16.5%) | 28 (6.2%) | 18 (15.4%) |
| G2 | 182 (41.0%) | 38 (38.4%) | 101 (41.7%) | 188 (41.6%) | 64 (54.7%) |
| G3 | 237 (53.4%) | 58 (58.6%) | 96 (41.8%) | 236 (52.2%) | 35 (29.9%) |
|
| |||||
| IHC subtype | |||||
| Luminal A-like | 132 (29.7%) | 28 (28.3%) | 89 (36.8%) | 89 (19.7%) | 72 (61,5.0%) |
| Luminal B-like | 163 (36.7%) | 37 (37.4%) | 94 (38.8%) | 113 (25.0%) | 21 (18,0%) |
| Her2+ | 48 (10.8%) | 13 (13.1%) | 17 (7.0%) | 72 (15.9%) | 7 (6.0%) |
| TNBC | 101 (22.7%) | 21 (21.2%) | 42 (17.4%) | 178 (39.4%) | 17 (14.5%) |
|
| |||||
| TILs | |||||
| Low | 210 (47.2%) | 49 (49.5%) | 140 (57.9%) | 219 (48.5%) | 60 (51.3%) |
| Intermediate | 161 (36.6%) | 41 (41.4%) | 73 (30.2%) | 182 (40.3%) | 47 (40.2%) |
| High | 73 (16.3%) | 9 (9.1%) | 29 (12.0%) | 51 (11.3%) | 10 (8.5%) |
|
| |||||
| PD-L1 expression by TILs | |||||
| Negative | 186 (41.9%) | 34 (34.3%) | 98 (40.5%) | 260 (57.5%) | 89 (76.2%) |
| Positive | 176 (39.6%) | 63 (63.6%) | 73 (30.2%) | 169 (37.4%) | 28 (23.8%) |
| Missing | 82 (18.5%) | 2 (2.1%) | 71 (29.3%) | 23 (5.1%) | 0 (0.0%) |
|
| |||||
| MHC class I expression | |||||
| HC (range) | 137.3 (0–300) | 201.1 (30–300) | 148.9 (10–300) | 113.3 (0–300) | 175.5 (10–300) |
| β2-m (range) | 166.5 (0–300) | 182.8 (0–300) | 193.0 (10–300) | 123.1 (0300) | 186.6 (40–300) |
*
Follow-up data were available from countries marked with an asterisk ().
Abbreviations Table 1: ß2-microglobuline, ß2-m, heavy chain, HC; human epidermal growth factor receptor 2 positive, Her2+; major histocompatibility complex, MHC; not applicable, N, number; NA; programmed death ligand-1, PD-L1; tumor-infiltrating lymphocytes, TILs; triple-negative BC, TNBC